Axsome Therapeutics is getting closer to becoming a profitable company, on a cash and earnings per share basis. An impressive quarter, with highlights below.
- Filed a new drug application for AXS-14 for Fibromyalgia
- On target to file a supplemental NDA for Alzheimer's Agitation 3rd Q
- Symbravo for acute migraine launch in June
- 300 million in cash
Chart below, as AXSM had a good day, after posting quarterly results. Thank you for reading.
No comments:
Post a Comment